Pola Sensitivitas Isolat Klinis Bakteri Gram Negatif Multiresisten Obat Terhadap Fosfomisin dari Beberapa Rumah Sakit Kota Pekanbaru

Dewi Anggraini, Atya Nasmah, Fauzia Andrini

Abstract

Over the last few years, there has been a decrease in amount of effective antibiotics, coincide with the lack of new antibiotics relevant for the treatment of Gram negative multi-drug resistant organisms infections. This problem can be overcome by the assessment and re-introduction of old antibiotics such as fosfomycin. Fosfomycin is a broad spectrum antibiotic that is bactericidal. This study aimed to find out the sensitivity pattern of clinical isolate multi-drug resistant Gram negative bacteria to fosfomycin with descriptive cross sectional method. The sample used in this study was clinical isolates collection of Microbiology Laboratory Faculty of Medicine, University of Riau from Hospitals in Pekanbaru. The result showedsensitivity to fosfomycin Escherichia coli producing ESBL (88%), Klebsiella pneumoniae producing ESBL (95%), Acinotobacter baumannii resistant meropenem (27%), Pseudomonas aeruginosa resistant meropenem (36%) and K.pneumoniae resistant meropenem (70%). Fosfomycin can be used as alternative therapy for infections caused by Gram-negative Multi-drug resistant organisms.

Keywords

fosfomycin, Gram-negative, multi-drug resistant organisms, pekanbaru

Full Text:

PDF

References

Dorland WA, Newman. Kamus kedokteran Dorland edisi 31, Jakarta: Penerbit Buku Kedokteran EGC;2010. p.567, 1003.

Peraturan Menteri Kesehatan Republik Indonesia No.8 Tahun 2015; Program pengendalian resistensi antimikroba di rumah sakit;2015.

Jane D. Siegel, MD; Emily Rhinehart, RN MPH CIC; Marguerite Jackson, PhD;

Linda Chiarello, RN MS; The healthcare infection control practices advisory committee. Management of multidrug-resistant organisms in healthcare setting;2017.p5-8.

O’Neil J. Review on antimicrobial resistance.antimicrobial resistance: tackling a crisis for the health and wealth of nation.2014;20-6

U.S. Department of Health and Human Services; Centers for Disease Control and Prevention; Antibiotic resistance threats In The United States;2013

Paraton H, Program pengendalian resistensi antimikroba di Rumah Sakit; Komite Pengendalian Resistensi Antibiotik;2016

Anggraini D, Pola resistensi RSUD Arifin Achmad tahun 2016;2016

Fosfomycin. Petunjuk penggunaan, deskripsi general anti-infeksi untuk penggunaan sistemik, Omedicine. Available from: URL;http://omedicine.info/id/fosfomycin.html

Dijikmans AC, Zacarias NVO, Burggraaf J, Mouton JW, Wilms EB, Nieuwkoop CV, Touw DJ, Stevens J, Kamerling IMC. Fosfomycin: Pharmacological, Clinical and Future Perspectives.2017;6(4): 24

Matthews C, Barrett L, Warren S, Stoesser N, Snelling, Scarborough M, Jones N. Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study. BMC Infectious Diseases (2016);2016.

Kuntaman K, Santoso S, Wahjono H, Mertaniasih NM, Lestari ES, Farida H, dkk. The Sensitivity pattern of extended spectrum beta lactamase-producing bacteria against six antibiotics that routinely used in clinical setting;j Indon Med Assoc:61:2011

Nurmala, Virgiandhy I, Andriani, Liana D. Resistensi dan sensitivitas bakteri terhadap antibiotik di RSU dr. Soedarso Pontianak Tahun 2011-2013;2013

Khan UI, Mirza IA, Ikram A, Ali S, Hussain A, Ghafoor T. In Vitro activity of fosfomycin tromethamine against extended spectrum beta-lactamase producing urinary tract bacteria. Journal of the College of Physicians and Surgeons Pakistan. 2014: 4(12); 914-917

Gupta V, Rani H, Singla N, Kaistha N, Chander J. Determination of extended-spectrum ß-lactamases and AmpC production in uropathogenic isolates of Escherichia coli and susceptibility to fosfomycin. J Lab Physicians 2013;5:90-3

Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin Microbiol Rev 2016;29:321-47.

Karageorgopoulos DE, Wang R, Xu-Hong Y, Falagas ME. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in gram-negative pathogens. J.Antimicrob. Chemother;2012 67:255–268. http://dx.doi.org/10.1093/jac/dkr466

Banerjee S, Sengupta M, Sarker TK. Fosfomycin susceptibility among multidrug-resistant, extended-spectrum beta-lactamase-producing, carbapenem-resistant uropathogens.2017;33.2.149-154

Bielen L, Likic R, Erdeljic V, Marekovic I, Firis N, Medic MG, Godan A, Tomic I, Hunjak B, Markotic A, Bejuk D, Ticic V, Balzar S, Bedenic B. Activity of fosfomycin against nosocomial multiresistant bacterial pathogens from Croatia: a multicentric study. Croat Med J. 2018;59:56-64 https://doi.org/10.3325/cmj.2018.59.56

Hoosen AA, Baba K. In-vitro activity of Fosfomycin against clinical isolates of carbapenem resistant Acinetobacter baumannii complex and Pseudomonas aeruginosa at a South African academic hospital. International Journal of Infectious Diseases 45S (2016) 1–477

Falagas ME, Kanellopoulou MD, Karageorgopoulos DE, Dimopoulos G, Rafailidis PI, Skarmoutsou ND, Papafrangas EA. Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin. Eur J Clin Microbiol Infect Dis. 2008 Jun;27(6):439-43. doi: 10.1007/s10096-007-0456-4

Abbott Jl, Cerqueira GM, Bhuiya S. Carbapenem resistance in Acinetobacter baumannii: Laboratory challenges, mechanistic insights and therapeutic strategies. Expert Review of Anti-infective Therapy 11(4):395-409:2013.

Clinical and Laboratory Standards Institute (CLSI), Performance Standards for Antimicrobia; Susceptibilit Testing 26th Edition;2016

Giguère S, Antimicrobial Drug Action and Interaction: An Introduction. Antimicrobial therapy in Veterinary Medicine 4th edn:USA;2006

Elizabeth AN, Sekeres J, Hall GS, Duin DV. Experience with fosfomycin for treatment of urinary tract infections due to Multidrug-Resistant Organisms. Antimicrobial Agents and Chemotherapy.2012;p. 5744–5748

Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: Use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 2008;46:1069‑77.

DOI: https://doi.org/10.26891/JIK.v13i1.2019.28-35

Refbacks

  • There are currently no refbacks.